UrologyNews.net

Urology Xagena

Xagena Mappa
Medical Meeting
Onco News
Farmaexplorer.it

Link between high blood concentrations of Omega-3 fatty acids and an increased risk of prostate cancer


A second large, prospective study by researchers at Fred Hutchinson Cancer Research Center ( Seattle; United States ) has confirmed the link between high blood concentrations of Omega-3 fatty acids and an increased risk of prostate cancer.

Published in he Journal of the National Cancer Institute ( JNCI ), the latest findings indicate that high concentrations of EPA, DPA and DHA, the three anti-inflammatory and metabolically related fatty acids derived from fatty fish and fish-oil supplements, are associated with a 71% increased risk of high-grade prostate cancer. The study also found a 44% increase in the risk of low-grade prostate cancer and an overall 43% increase in risk for all prostate cancers.

The findings confirm a 2011 study published by the same Fred Hutch scientific team that reported a similar link between high blood concentrations of DHA and a more than doubling of the risk for developing high-grade prostate cancer. The latest study also confirms results from a large European study.
The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis.

It is unclear from this study why high levels of Omega-3 fatty acids would increase prostate cancer risk, however the replication of this finding in two large studies indicates the need for further research into possible mechanisms. One potentially harmful effect of Omega-3 fatty acids is their conversion into compounds that can cause damage to cells and DNA, and their role in immunosuppression. Whether these effects impact cancer risk is not known.

The difference in blood concentrations of Omega-3 fatty acids between the lowest and highest risk groups was about 2.5 percentage points ( 3.2% vs. 5.7% ).

The current study analyzed data and specimens collected from men who participated in the Selenium and Vitamin E Cancer Prevention Trial ( SELECT ), a large randomized, placebo-controlled trial to test whether Selenium and Vitamin E, either alone or combined, reduced prostate cancer risk. That study showed no benefit from Selenium intake and an increase in prostate cancers in men who took Vitamin E.

The group included in this analysis consisted of 834 men who had been diagnosed with incident, primary prostate cancers ( 156 were high-grade cancer ) along with a comparison group of 1,393 men selected randomly from the 35,500 participants in SELECT. ( Xagena )

Source: Fred Hutchinson Cancer Research Center, 2013

XagenaMedicine_2013



Indietro